Emerging Approaches in Data-Driven Drug Discovery for Rare Diseases

Area of Science:

• Pharmacology and Computational Biology
• Drug Discovery and Development

Background:

• Rare diseases pose significant challenges in drug discovery due to small patient populations and data limitations.
• Traditional drug development struggles with the genetic variability and complex mechanisms of rare diseases.

Purpose of the Study:

• To review the integration of pharmacokinetic (PK) and drug metabolism data into data-driven approaches for rare disease drug discovery.
• To explore the role of Artificial Intelligence (AI) and Machine Learning (ML) in optimizing drug candidates and predicting therapeutic strategies.

Main Methods:

• Integration of PK/ADME (absorption, distribution, metabolism, excretion) data with computational techniques like AI and ML.
• Analysis of enzyme-drug interactions, metabolic pathways, and AI-based PK simulations.
• Evaluation of PK/PD (pharmacodynamics) models combined with multi-omics data.

Main Results:

• AI and ML enhance prediction of PK parameters and drug behavior in diverse populations.
• Integration with genomic and proteomic data identifies novel therapeutic pathways.
• Computational approaches improve predictive accuracy, drug safety, and reduce development timelines and costs.

Conclusions:

• Integrating PK and metabolism studies within data-driven frameworks is crucial for rare disease drug discovery.
• AI-powered approaches accelerate therapeutic innovation and address unmet medical needs for rare disease patients.
• Interdisciplinary collaboration enhances the precision and effectiveness of tailored treatments.